Study #2023-0233
A phase 1a/1b study investigating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the DGKZ; inhibitor BGB-30813, alone or in combination with the ANTI-PD-1 monoclonal antibody Tislelizumab in patients with advanced or metastatic solid tumors.
MD Anderson Study Status
Enrolling
Treatment Agent
BGB-30813, Tislelizumab
Description
This is a First in Human (FIH) Phase 1, multicenter, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-30813 as monotherapy or in combination with tislelizumab in participants with advanced or metastatic solid tumors. The study will be conducted in 2 parts: Phase 1a dose escalation and Phase 1b dose expansion.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumors
Study phase:
Phase I
Physician name:
Siqing Fu
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-833-922-0089
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.